Eli Lilly and Peptron maintain an active evaluation agreement, originally signed in October 2024 and extended to a maximum of 24 months, focused on non-commercial, internal R&D testing of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates. This setup has not progressed to any announced commercial licensing, technology transfer, or binding deal for rights. Lilly’s separate, larger partnership with Camurus for its FluidCrystal long-acting injectable technology—covering multiple incretin assets—has reinforced trader views that SmartDepot faces strong competition and lower priority. With the October 7, 2026 deadline approaching and no recent catalysts or statements indicating imminent commercialization, market-implied odds heavily favor “No.”
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
$11,138 Vol.
$11,138 Vol.
7 ott 2026
$11,138 Vol.
$11,138 Vol.
7 ott 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain an active evaluation agreement, originally signed in October 2024 and extended to a maximum of 24 months, focused on non-commercial, internal R&D testing of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates. This setup has not progressed to any announced commercial licensing, technology transfer, or binding deal for rights. Lilly’s separate, larger partnership with Camurus for its FluidCrystal long-acting injectable technology—covering multiple incretin assets—has reinforced trader views that SmartDepot faces strong competition and lower priority. With the October 7, 2026 deadline approaching and no recent catalysts or statements indicating imminent commercialization, market-implied odds heavily favor “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercato aperto: May 5, 2026, 8:02 PM ET
Volume
$11,138Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain an active evaluation agreement, originally signed in October 2024 and extended to a maximum of 24 months, focused on non-commercial, internal R&D testing of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates. This setup has not progressed to any announced commercial licensing, technology transfer, or binding deal for rights. Lilly’s separate, larger partnership with Camurus for its FluidCrystal long-acting injectable technology—covering multiple incretin assets—has reinforced trader views that SmartDepot faces strong competition and lower priority. With the October 7, 2026 deadline approaching and no recent catalysts or statements indicating imminent commercialization, market-implied odds heavily favor “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,138Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron maintain an active evaluation agreement, originally signed in October 2024 and extended to a maximum of 24 months, focused on non-commercial, internal R&D testing of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates. This setup has not progressed to any announced commercial licensing, technology transfer, or binding deal for rights. Lilly’s separate, larger partnership with Camurus for its FluidCrystal long-acting injectable technology—covering multiple incretin assets—has reinforced trader views that SmartDepot faces strong competition and lower priority. With the October 7, 2026 deadline approaching and no recent catalysts or statements indicating imminent commercialization, market-implied odds heavily favor “No.”
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti